Moreover, subsequent studies have shown that positive pre-treatment serum AFP-L3% predicts tumor progression, recurrence and poor clinical outcome [6]–[8], and it has superior prognostic accuracy as a tumor marker compared with AFP or DCP [9], [10]. This evidence concerns the gene ACE and neoplasm.